Nephrologists Transforming Dialysis Safety

 View Only

Welcome to the Nephrologists Transforming Dialysis Safety ASN Community Website.  You will need to Sign In to access the Community discussions and resources.

  • If you have an ASN-Online.org user name and password, select  the "Sign In" button in the top right corner of this page. 
  • If you do not have a free user name and password, you can get one from ASN-Online.org.  Once you have your free registration, you will be redirected to this site and you can Sign In with your new user name and password.  

Latest Discussion Posts

Please login to see all eligible discussion postings

Either the content you're seeking doesn't exist or it requires proper authentication before viewing.

Community Minded

Proliferative glomerulonephritis with monoclonal IgG kappa deposits  
A 50-year-old man presents with rapidly progressive glomerulonephritis (RPGN) requiring dialysis. Creatinine is 2.4 and rising. A kidney biopsy demonstrates proliferative glomerulonephritis with monoclonal IgG kappa deposits (PGNMID). Interstitial fibrosis tubular atrophy (IFTA) is 10%. Pulse steroid therapy is performed and after a full paraprotein work-up no monoclonal protein is detected in blood or urine. A bone marrow aspirate and trephine biopsy (BMAT) shows no lymphocyte or plasma cell clonal population. No lymphadenopathy is present. How do you target a clone when no clone is found: bortezomib, rituximab or even daratumumab? Share your thoughts. 

Summary provided by Roger Rodby, MD, FASN.
Previous Community Minded Summaries are available at: https://community.asn-online.org/browse/communityminded 

Community Leaders